This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Viral Infections  • Adverse Effects  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic

A Case Report

Laura Rosiñol, MD; Silvia Montoto, MD; Maria Teresa Cibeira, MD; Joan Bladé, MD

Arch Intern Med. 2005;165:464-465.

Bortezomib is a novel proteasome inhibitor with significant antimyeloma activity. Its toxicity is manageable, and the most frequent adverse effects mainly consist of gastrointestinal symptoms, peripheral neuropathy, neuropatic pain, and thrombocytopenia. Severe liver toxicity has not been previously recognized. A patient with relapsed multiple myeloma who developed bortezomib-induced severe recurrent hepatitis is described. The importance of recognizing this rare potential toxicity is highlighted in order to discontinue this agent if liver adverse reaction is suspected.

Author Affiliations: Hematology Department, Institut d’Investigacions Biomèdiques August Pi I Sunyer, Hospital Clínic, Barcelona, Spain.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma
San Miguel et al.
The Oncologist 2006;11:51-61.
ABSTRACT | FULL TEXT